[Form 4] NeuroPace Inc Insider Trading Activity
NeuroPace director Kumar Rakhi received 1,509 shares of common stock as compensation on 09/19/2025 at a price of $9.94 per share. These shares were issued under the company’s non-employee director compensation policy in lieu of quarterly retainer fees, increasing the reporting person’s total beneficial ownership to 17,103 shares following the transaction.
The Form 4 reports this as a non-derivative acquisition and was filed as a single-person report. The disclosure identifies the transaction code as an issuance for compensation and states the reporting person’s relationship to the issuer as a director.
Il direttore di NeuroPace, Kumar Rakhi, ha ricevuto 1.509 azioni ordinarie come compenso il 19/09/2025 al prezzo di 9,94 dollari per azione. Queste azioni sono state emesse ai sensi della politica di compensazione per i diretti non dipendenti, in sostituzione delle commissioni trimestrali, aumentando la proprietà beneficiaria totale del soggetto a 17.103 azioni a seguito della transazione.
Il modulo 4 riporta questa acquisizione come non derivativa ed è stato presentato come rapporto per una sola persona. La divulgazione identifica il codice di operazione come emissione per compenso e indica la relazione del soggetto segnalante con l’emittente come direttore.
El director de NeuroPace, Kumar Rakhi, recibió 1.509 acciones ordinarias como compensación el 19/09/2025 a un precio de 9,94 dólares por acción. Estas acciones se emitieron conforme a la política de compensación para directores no empleados en lugar de honorarios trimestrales, aumentando la propiedad beneficiosa total del informante a 17.103 acciones tras la transacción.
El Formulario 4 reporta esto como una adquisición no derivativa y se presentó como un informe de persona única. La divulgación identifica el código de transacción como emisión por compensación y señala la relación del informante con el emisor como director.
네우로페이스의 이사 쿠마르 라키는 2025년 9월 19일 보상으로 일반주 1,509주를 받았으며 주당 가격은 9.94달러입니다. 이 주식은 분기 고정 보수를 대신해 비고용 이사 보상 정책에 따라 발행되었고, 거래 후 보고인의 총 보유 주식 수는 17,103주로 증가했습니다.
폼 4는 이를 비파생적 취득으로 보고했고 1인 신고서로 제출되었습니다. 공시는 거래 코드를 보상으로의 발행으로 식별하며, 보고자와 발행자의 관계를 이사로 명시합니다.
Le directeur de NeuroPace, Kumar Rakhi, a reçu 1 509 actions ordinaires en tant que rémunération le 19/09/2025, à un prix de 9,94 dollars par action. Ces actions ont été émises en vertu de la politique de rémunération des administrateurs non salariés, en remplacement des frais trimestriels, portant la détention bénéficiaire totale du déclarant à 17 103 actions après la transaction.
Le Formulaire 4 indique ceci comme une acquisition non dérivée et a été déposé comme rapport individuel. La divulgation identifie le code de transaction comme une émission pour rémunération et indique que la relation du déclarant avec l’émetteur est celle d’un administrateur.
Der NeuroPace-Direktor Kumar Rakhi erhielt am 19.09.2025 1.509 Stammaktien als Vergütung zu einem Preis von 9,94 USD pro Aktie. Diese Aktien wurden gemäß der Richtlinie zur Vergütung von nicht-angestellten Direktoren ausgegeben, anstelle vierteljährlicher Retainer-Gebühren, wodurch das gesamte wirtschaftliche Eigentum der meldenden Person nach der Transaktion auf 17.103 Aktien anwuchs.
Das Formular 4 meldet dies als nicht-derivative Erwerb und es wurde als Einzelberichte eingereicht. Die Offenlegung identifiziert den Transaktionscode als Ausgabe zur Vergütung und gibt die Beziehung der meldenden Person zum Emittenten als Direktoren an.
تلقى مدير NeuroPace، كومار راخي، 1,509 سهماً عاديًا كتعويض في 19/09/2025 بسعر 9.94 دولاراً للسهم الواحد. صدرت هذه الأسهم وفق سياسة تعويض المدراء غير الموظفين بدلاً من رسوم الاحتياج الربع السنوية، مما زاد الملكية المفيدة الإجمالية للمبلّغ عن الصفقة إلى 17,103 سهمًا بعد الصفقة.
يذكر النموذج 4 أن هذا يمثل اكتساباً غير مشتق وتم تقديمه كتقرير لشخص واحد. تكشف الإفصاح عن رمز المعاملة كإصدار للتعويض وتذكر أن علاقة المبلّغ به مع الجهة المصدرة هي كمدير.
NeuroPace 董事 Kumar Rakhi 于 2025-09-19 以每股 9.94 美元的价格获得 1,509 股普通股作为报酬。 这些股份是按照公司非雇员董事薪酬政策发行，以代替季度报酬，交易完成后报告人拥有的总股权增至 17,103 股。
Form 4 将此列为非衍生取得，并作为个人报告提交。披露将交易代码标识为因薪酬而发行，并说明报告人与发行人之间的关系为董事。
- Director ownership increased to 17,103 shares after the issuance, aligning director and shareholder interests
- Shares issued as compensation under the company’s non-employee director policy, indicating routine governance practice
- None.
Insights
TL;DR: Routine director compensation issuance increases insider ownership modestly; no indication of open-market trading or unusual timing.
The Form 4 documents a standard non-employee director equity grant issued instead of cash retainer fees. Such issuances are common governance practices to align directors’ interests with shareholders and to conserve cash. The report shows a modest incremental stake resulting in 17,103 shares beneficially owned. Because the shares were compensation-based and not purchased on the open market, this filing does not signal a trading decision by the director and is typically treated as routine disclosure.
TL;DR: Small, compensatory share issuance with limited likely market impact given size and nature of the transaction.
The transaction recorded is an issuance of 1,509 common shares at $9.94 per share under the issuer’s director compensation policy. This increases insider holdings to 17,103 shares, a relatively small absolute holding absent additional context on total outstanding shares. The form classifies the event as a non-derivative acquisition for compensation purposes, which typically has limited informational content regarding the company’s operational prospects.
Il direttore di NeuroPace, Kumar Rakhi, ha ricevuto 1.509 azioni ordinarie come compenso il 19/09/2025 al prezzo di 9,94 dollari per azione. Queste azioni sono state emesse ai sensi della politica di compensazione per i diretti non dipendenti, in sostituzione delle commissioni trimestrali, aumentando la proprietà beneficiaria totale del soggetto a 17.103 azioni a seguito della transazione.
Il modulo 4 riporta questa acquisizione come non derivativa ed è stato presentato come rapporto per una sola persona. La divulgazione identifica il codice di operazione come emissione per compenso e indica la relazione del soggetto segnalante con l’emittente come direttore.
El director de NeuroPace, Kumar Rakhi, recibió 1.509 acciones ordinarias como compensación el 19/09/2025 a un precio de 9,94 dólares por acción. Estas acciones se emitieron conforme a la política de compensación para directores no empleados en lugar de honorarios trimestrales, aumentando la propiedad beneficiosa total del informante a 17.103 acciones tras la transacción.
El Formulario 4 reporta esto como una adquisición no derivativa y se presentó como un informe de persona única. La divulgación identifica el código de transacción como emisión por compensación y señala la relación del informante con el emisor como director.
네우로페이스의 이사 쿠마르 라키는 2025년 9월 19일 보상으로 일반주 1,509주를 받았으며 주당 가격은 9.94달러입니다. 이 주식은 분기 고정 보수를 대신해 비고용 이사 보상 정책에 따라 발행되었고, 거래 후 보고인의 총 보유 주식 수는 17,103주로 증가했습니다.
폼 4는 이를 비파생적 취득으로 보고했고 1인 신고서로 제출되었습니다. 공시는 거래 코드를 보상으로의 발행으로 식별하며, 보고자와 발행자의 관계를 이사로 명시합니다.
Le directeur de NeuroPace, Kumar Rakhi, a reçu 1 509 actions ordinaires en tant que rémunération le 19/09/2025, à un prix de 9,94 dollars par action. Ces actions ont été émises en vertu de la politique de rémunération des administrateurs non salariés, en remplacement des frais trimestriels, portant la détention bénéficiaire totale du déclarant à 17 103 actions après la transaction.
Le Formulaire 4 indique ceci comme une acquisition non dérivée et a été déposé comme rapport individuel. La divulgation identifie le code de transaction comme une émission pour rémunération et indique que la relation du déclarant avec l’émetteur est celle d’un administrateur.
Der NeuroPace-Direktor Kumar Rakhi erhielt am 19.09.2025 1.509 Stammaktien als Vergütung zu einem Preis von 9,94 USD pro Aktie. Diese Aktien wurden gemäß der Richtlinie zur Vergütung von nicht-angestellten Direktoren ausgegeben, anstelle vierteljährlicher Retainer-Gebühren, wodurch das gesamte wirtschaftliche Eigentum der meldenden Person nach der Transaktion auf 17.103 Aktien anwuchs.
Das Formular 4 meldet dies als nicht-derivative Erwerb und es wurde als Einzelberichte eingereicht. Die Offenlegung identifiziert den Transaktionscode als Ausgabe zur Vergütung und gibt die Beziehung der meldenden Person zum Emittenten als Direktoren an.
FAQ
What transaction did Kumar Rakhi report on NeuroPace (NPCE)?
Why were the shares issued to the reporting person?
How many NeuroPace shares does the reporting person beneficially own after the transaction?
Was this Form 4 filed jointly or by one reporting person?
Does the filing indicate open-market purchases or sales by the director?
